Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathological and clinical response of a primary chemotherapy regimen combining vinorelbine, epirubicin, and paclitaxel as neoadjuvant treatment in patients with operable breast cancer.
Abrial C, Van Praagh I, Delva R, Leduc B, Fleury J, Gamelin E, Sillet-Bach I, Penault-Llorca F, Amat S, Chollet P. Abrial C, et al. Among authors: van praagh i. Oncologist. 2005 Apr;10(4):242-9. doi: 10.1634/theoncologist.10-4-242. Oncologist. 2005. PMID: 15821244 Free article. Clinical Trial.
Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer.
Wang-Lopez Q, Mouret-Reynier MA, Savoye AM, Abrial C, Kwiatkowski F, Garbar C, DuBray-Longeras P, Eymard JC, Lebouedec G, Vanpraagh I, Penault-Llorca F, Chollet P, Cure H. Wang-Lopez Q, et al. Oncologist. 2015 Mar;20(3):243-4. doi: 10.1634/theoncologist.2014-0400. Epub 2015 Jan 30. Oncologist. 2015. PMID: 25637380 Free PMC article. Clinical Trial.
Everolimus in Metastatic Breast Cancer: Clinical Experience as a Late Treatment Line.
Pouget M, Abrial C, Planchat E, Van Praagh I, Arbre M, Kwiatkowski F, Dubray-Longeras P, Devaud H, Dohou J, Herviou P, Mahammedi H, Durando X, Chollet P, Mouret-Reynier MA. Pouget M, et al. Among authors: van praagh i. Oncology. 2015;89(6):319-31. doi: 10.1159/000437230. Epub 2015 Oct 13. Oncology. 2015. PMID: 26457979
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Mahammedi H, Planchat E, Pouget M, Durando X, Curé H, Guy L, Van-Praagh I, Savareux L, Atger M, Bayet-Robert M, Gadea E, Abrial C, Thivat E, Chollet P, Eymard JC. Mahammedi H, et al. Among authors: van praagh i. Oncology. 2016;90(2):69-78. doi: 10.1159/000441148. Epub 2016 Jan 16. Oncology. 2016. PMID: 26771576 Clinical Trial.
Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Nabholtz JM, Abrial C, Mouret-Reynier MA, Dauplat MM, Weber B, Gligorov J, Forest AM, Tredan O, Vanlemmens L, Petit T, Guiu S, Van Praagh I, Jouannaud C, Dubray-Longeras P, Tubiana-Mathieu N, Benmammar KE, Kullab S, Bahadoor MR, Radosevic-Robin N, Kwiatkowski F, Desrichard A, Cayre A, Uhrhammer N, Chalabi N, Chollet P, Penault-Llorca F. Nabholtz JM, et al. Among authors: van praagh i. Ann Oncol. 2014 Aug;25(8):1570-7. doi: 10.1093/annonc/mdu183. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827135 Free article. Clinical Trial.
36 results